Literature DB >> 2137061

Sickness absence among insulin-treated diabetic employees.

E R Waclawski1.   

Abstract

The aim of the present study was to investigate the sickness absence of insulin-treated diabetic employees. A case-control study using company sickness absence records for 1986 was performed on 59 diabetic patients and 59 control subjects matched by age, sex, and occupation. The patients had a similar frequency of absence to the control subjects (2.0 (range 0-7) and 1.7 (0-7) episodes yr-1, respectively). However, diabetic employees lost a larger number of working days (13.3 (0-101) vs 5.7 (0-52) days yr-1, p less than 0.03), and had a greater average length of episode of absence (5.6 (0-55) vs 2.5 (0-28) days, p less than 0.02). Males, manual workers, and those under 40 years of age accounted for significantly greater absence, but absence was also greater for diabetic employees than for control subjects in the other groups. Ten or more days were lost by 21 diabetic employees, but only 10 control subjects in 1986 (p less than 0.05).

Entities:  

Mesh:

Year:  1990        PMID: 2137061     DOI: 10.1111/j.1464-5491.1990.tb01305.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  4 in total

1.  Health-related and work-related aspects associated with sick leave: a comparison of chronically ill and non-chronically ill workers.

Authors:  K Roskes; N C G M Donders; J W J van der Gulden
Journal:  Int Arch Occup Environ Health       Date:  2005-03-25       Impact factor: 3.015

2.  Sickness absence in diabetic employees.

Authors:  A Skerjanc
Journal:  Occup Environ Med       Date:  2001-07       Impact factor: 4.402

3.  Sickness absence in diabetic employees at a large engineering factory.

Authors:  C J Poole; D Gibbons; I A Calvert
Journal:  Occup Environ Med       Date:  1994-05       Impact factor: 4.402

4.  Quality of centralized diabetes care: a population-based study in the German Democratic Republic 1989-1990.

Authors:  U A Müller; I S Ross; H Klinger; S Geisenheiner; E A Chantelau
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.